Posted by Michael Wonder on 17 Jul 2023
FDA approves new drug to prevent RSV in babies and toddlers
17 July 2023 - Today, the US FDA approved Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants born during or entering their first respiratory syncytial virus season, and in children up to 24 months of age who remain vulnerable to severe respiratory syncytial virus disease through their second respiratory syncytial virus season.
The safety and efficacy of Beyfortus were supported by three clinical trials.
